.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM05_Parsaclisib.Parsaclisib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM05_Parsaclisib.Parsaclisib| name: | Parsaclisib |
| ATC code: | L01EM05 | route: | oral |
| n-compartments | 2 |
Parsaclisib is an oral, selective PI3Kδ inhibitor developed for the treatment of relapsed or refractory B-cell malignancies, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. It is not broadly FDA approved as of June 2024, but has been studied in clinical trials.
Pharmacokinetic parameters from adult patients with B-cell malignancies receiving oral parsaclisib. Most PK data are from phase 1/2 clinical trials in this patient population.
Fukuhara, N, et al., & Izutsu, K (2022). Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study. Cancer science 113(5) 1702–1711. DOI:10.1111/cas.15308 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35201656